Yiru Fang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6582088/publications.pdf

Version: 2024-02-01

171 papers	8,190 citations	109321 35 h-index	58581 82 g-index
173 all docs	173 docs citations	173 times ranked	17945 citing authors

#	Article	IF	Citations
1	Peripheral biomarkers to predict the diagnosis of bipolar disorder from major depressive disorder in adolescents. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 817-826.	3.2	14
2	Difference in the regulation of biological rhythm symptoms of Major depressive disorder between escitalopram and mirtazapine. Journal of Affective Disorders, 2022, 296, 258-264.	4.1	3
3	Impaired robust interhemispheric function integration of depressive brain from RESTâ€metaâ€MDD database in China. Bipolar Disorders, 2022, 24, 400-411.	1.9	8
4	Evaluating the efficacy and moderators of algorithm-guided antidepressant treatments of major depressive disorder. Journal of Affective Disorders, 2022, 297, 68-75.	4.1	1
5	A Breakthrough in Understanding the Rapid Antidepressant Effect of Ketamine Based on Structural Analysis. Neuroscience Bulletin, 2022, 38, 229-231.	2.9	2
6	A Preliminary Study of Different Treatment Strategies for Anxious Depression. Neuropsychiatric Disease and Treatment, 2022, Volume 18, 11-18.	2.2	0
7	Bilateral Habenula deep brain stimulation for treatment-resistant depression: clinical findings and electrophysiological features. Translational Psychiatry, 2022, 12, 52.	4.8	21
8	Prevalence, clinical features and prescription patterns of psychotropic medications for patients with psychotic depression in China. Journal of Affective Disorders, 2022, 301, 248-252.	4.1	3
9	The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication. Signal Transduction and Targeted Therapy, 2022, 7, 57.	17.1	34
10	Phenotypes, mechanisms and therapeutics: insights from bipolar disorder GWAS findings. Molecular Psychiatry, 2022, 27, 2927-2939.	7.9	17
11	Analysis of Seasonal Clinical Characteristics in Patients With Bipolar or Unipolar Depression. Frontiers in Psychiatry, 2022, 13, 847485.	2.6	1
12	Employing biochemical biomarkers for building decision tree models to predict bipolar disorder from major depressive disorder. Journal of Affective Disorders, 2022, 308, 190-198.	4.1	10
13	Early Diagnosis of Bipolar Disorder Coming Soon: Application of an Oxidative Stress Injury Biomarker (BIOS) Model. Neuroscience Bulletin, 2022, 38, 979-991.	2.9	8
14	Exploring the Core Genes of Schizophrenia Based on Bioinformatics Analysis. Genes, 2022, 13, 967.	2.4	2
15	Short- and Long-Term Influences of Benzodiazepine and Z-Drug Use in Patients with Bipolar Disorder Combined Sleep Disturbance during Affective Period: A Nine-Month Follow-Up Analysis. Disease Markers, 2022, 2022, 1-7.	1.3	1
16	Reduced nucleus accumbens functional connectivity in reward network and default mode network in patients with recurrent major depressive disorder. Translational Psychiatry, 2022, 12, .	4.8	20
17	Novel Risk Loci Associated With Genetic Risk for Bipolar Disorder Among Han Chinese Individuals. JAMA Psychiatry, 2021, 78, 320.	11.0	35
18	Independent replications and integrative analyses confirm TRANK1 as a susceptibility gene for bipolar disorder. Neuropsychopharmacology, 2021, 46, 1103-1112.	5.4	20

#	Article	IF	Citations
19	Probing the clinical and brain structural boundaries of bipolar and major depressive disorder. Translational Psychiatry, 2021, 11, 48.	4.8	9
20	Major Depressive Disorder: Advances in Neuroscience Research and Translational Applications. Neuroscience Bulletin, 2021, 37, 863-880.	2.9	107
21	Disturbances of affective cognition in mood disorders. Science China Life Sciences, 2021, 64, 938-941.	4.9	3
22	PTEN in prefrontal cortex is essential in regulating depression-like behaviors in mice. Translational Psychiatry, 2021, 11, 185.	4.8	21
23	Lower Health Literacy of Mania Than Depression Among Older People: A Random Survey of a Community Healthcare Service Center. Frontiers in Psychiatry, 2021, 12, 512689.	2.6	2
24	Disrupted hemispheric connectivity specialization in patients with major depressive disorder: Evidence from the REST-meta-MDD Project. Journal of Affective Disorders, 2021, 284, 217-228.	4.1	23
25	PAID study design on the role of PKC activation in immune/inflammation-related depression: a randomised placebo-controlled trial protocol. Annals of General Psychiatry, 2021, 34, e100440.	3.1	3
26	Hypothalamic-Pituitary-End-Organ Axes: Hormone Function in Female Patients with Major Depressive Disorder. Neuroscience Bulletin, 2021, 37, 1176-1187.	2.9	14
27	Can seizure therapies and noninvasive brain stimulations prevent suicidality? A systematic review. Brain and Behavior, 2021, 11, e02144.	2.2	8
28	Cognitive control and emotional response in attention-deficit/ hyperactivity disorder comorbidity with disruptive, impulse-control, and conduct disorders. BMC Psychiatry, 2021, 21, 232.	2.6	6
29	Gene expression signatures differentiating major depressive disorder from subsyndromal symptomatic depression. Aging, 2021, 13, 13124-13137.	3.1	2
30	Gastrointestinal Symptoms During Depressive Episodes in 3256 Patients with Major Depressive Disorders: Findings from the NSSD. Journal of Affective Disorders, 2021, 286, 27-32.	4.1	15
31	Clinical features of the patients with major depressive disorder co-occurring insomnia and hypersomnia symptoms: a report of NSSD study. Sleep Medicine, 2021, 81, 375-381.	1.6	13
32	Predictors and moderators of quality of life in patients with major depressive disorder: An AGTs-MDD study report. Journal of Psychiatric Research, 2021, 138, 96-102.	3.1	5
33	Schizophrenia, bipolar disorder, or intracranial aneurysm? A case report. Brain and Behavior, 2021, 11, e2245.	2.2	2
34	A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 2441-2449.	2.2	0
35	Disrupted intrinsic functional brain topology in patients with major depressive disorder. Molecular Psychiatry, 2021, 26, 7363-7371.	7.9	82
36	Barriers and facilitators to implementing measurement-based care for depression in Shanghai, China: a situational analysis. BMC Psychiatry, 2021, 21, 430.	2.6	4

#	Article	IF	Citations
37	The effect of thyroid function on the risk of psychiatric readmission after hospitalization for major depressive disorder. Psychiatry Research, 2021, 305, 114205.	3.3	7
38	Neural biomarker of functional disability in major depressive disorder: A structural neuroimaging study. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110337.	4.8	2
39	Brain structural alterations in MDD patients with gastrointestinal symptoms: Evidence from the REST-meta-MDD project. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 111, 110386.	4.8	18
40	Exploring the Effects of Temperament on Gray Matter Volume of Frontal Cortex in Patients with Mood Disorders. Neuropsychiatric Disease and Treatment, 2021, Volume 17, 183-193.	2.2	5
41	Comorbidity and Treatment in Older Psychiatric In-patientsâ€"A Retrospective Study in a Chinese Psychiatric Hospital. Frontiers in Psychiatry, 2021, 12, 722329.	2.6	1
42	Weighted gene co-expression network analysis identifies specific modules and hub genes related to subsyndromal symptomatic depression. World Journal of Biological Psychiatry, 2020, 21, 102-110.	2.6	10
43	Symptomatology differences of major depression in psychiatric versus general hospitals: A machine learning approach. Journal of Affective Disorders, 2020, 260, 349-360.	4.1	7
44	Causes of drug discontinuation in patients with major depressive disorder in China. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2020, 96, 109755.	4.8	23
45	Does early and late life depression differ in residual symptoms, functioning and quality of life among the first-episode major depressive patients. Asian Journal of Psychiatry, 2020, 47, 101843.	2.0	11
46	Altered resting-state dynamic functional brain networks in major depressive disorder: Findings from the REST-meta-MDD consortium. NeuroImage: Clinical, 2020, 26, 102163.	2.7	76
47	Common cellular and molecular mechanisms and interactions between microglial activation and aberrant neuroplasticity in depression. Neuropharmacology, 2020, 181, 108336.	4.1	17
48	COVIDâ€19 and postâ€traumatic stress disorder: A vicious circle involving immunosuppression. CNS Neuroscience and Therapeutics, 2020, 26, 876-878.	3.9	25
49	Biotypes of major depressive disorder: Neuroimaging evidence from resting-state default mode network patterns. NeuroImage: Clinical, 2020, 28, 102514.	2.7	51
50	Mental Health Service Challenges during the Early Stage of the COVID-19 Pandemic: Experience and Best Practices from China. Canadian Journal of Psychiatry, 2020, 66, 070674372097225.	1.9	5
51	Lack of Association Between PLA2G6 Genetic Variation and Parkinsonâ€™s Disease: A Systematic Review . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 1755-1763.	2.2	4
52	Reliability and Validity of THINC-it in Evaluating Cognitive Function of Patients with Bipolar Depression . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2419-2428.	2.2	10
53	Altered resting-state fMRI signals and network topological properties of bipolar depression patients with anxiety symptoms. Journal of Affective Disorders, 2020, 277, 358-367.	4.1	12
54	The Developmental and Translational Study on Biomarkers and Clinical Characteristics-based Diagnostic and Therapeutic Identification of Major Depressive Disorder: Study Protocol for a Multicenter Randomized Controlled Trial in China . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2343-2351.	2.2	1

#	Article	IF	Citations
55	Functional Status of Hypothalamicâ€“Pituitaryâ€“Thyroid and Hypothalamicâ€“Pituitaryâ€“Adrenal Axes in Hospitalized Schizophrenics in Shanghai. Frontiers in Psychiatry, 2020, 11, 65.	2.6	19
56	The relationship of olfactory function and clinical traits in major depressive disorder. Behavioural Brain Research, 2020, 386, 112594.	2.2	10
57	Identification of a functional human-unique 351-bp Alu insertion polymorphism associated with major depressive disorder in the 1p31.1 GWAS risk loci. Neuropsychopharmacology, 2020, 45, 1196-1206.	5.4	17
58	Ifenprodil rapidly ameliorates depressive-like behaviors, activates mTOR signaling and modulates proinflammatory cytokines in the hippocampus of CUMS rats. Psychopharmacology, 2020, 237, 1421-1433.	3.1	22
59	Potential contribution of increased soluble IL-2R to lymphopenia in COVID-19 patients. Cellular and Molecular Immunology, 2020, 17, 878-880.	10.5	45
60	The Risk and Prevention of Novel Coronavirus Pneumonia Infections Among Inpatients in Psychiatric Hospitals. Neuroscience Bulletin, 2020, 36, 299-302.	2.9	178
61	Variants in the Upstream Region of the Insulin Receptor Substrate-1 Gene Is Associated with Major Depressive Disorder in the Han Chinese Population . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 501-507.	2.2	1
62	Association between residual symptoms and social functioning in patients with depression. Comprehensive Psychiatry, 2020, 98, 152164.	3.1	10
63	Role of biological rhythm dysfunction in the development and management of bipolar disorders: a review. Annals of General Psychiatry, 2020, 33, e100127.	3.1	9
64	Clinical and immunological features of severe and moderate coronavirus disease 2019. Journal of Clinical Investigation, 2020, 130, 2620-2629.	8.2	3,820
65	Cortical thickness and subcortical volumes alterations in euthymic bipolar I patients treated with different mood stabilizers. Brain Imaging and Behavior, 2019, 13, 1255-1264.	2.1	8
66	Clinical characteristics associated with therapeutic nonadherence of the patients with major depressive disorder: A report on the National Survey on Symptomatology of Depression in China. CNS Neuroscience and Therapeutics, 2019, 25, 215-222.	3.9	8
67	Cognitive symptoms in major depressive disorder: associations with clinical and functional outcomes in a 6-month, non-interventional, prospective study in China . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 1723-1736.	2.2	25
68	Perspective on Etiology and Treatment of Bipolar Disorders in China: Clinical Implications and Future Directions. Neuroscience Bulletin, 2019, 35, 608-612.	2.9	5
69	Preliminary Clinical Investigation of Combinatorial Pharmacogenomic Testing for the Optimized Treatment of Depression: A Randomized Single-Blind Study. Frontiers in Neuroscience, 2019, 13, 960.	2.8	15
70	The Relationship Between Neuroimmunity and Bipolar Disorder: Mechanism and Translational Application. Neuroscience Bulletin, 2019, 35, 595-607.	2.9	19
71	Detection Study of Bipolar Depression Through the Application of a Model-Based Algorithm in Terms of Clinical Feature and Peripheral Biomarkers. Frontiers in Psychiatry, 2019, 10, 266.	2.6	7
72	Editorial: Involvement of Neuro-Immune Mechanism and Brainâ€“Gut Axis in Pathophysiology of Mood Disorders. Frontiers in Psychiatry, 2019, 10, 403.	2.6	2

#	Article	IF	Citations
73	Perception of Stigma and Its Associated Factors Among Patients With Major Depressive Disorder: A Multicenter Survey From an Asian Population. Frontiers in Psychiatry, 2019, 10, 321.	2.6	26
74	Disagreement and factors between symptom on self-report and clinician rating of major depressive disorder: A report of a national survey in China. Journal of Affective Disorders, 2019, 253, 141-146.	4.1	10
75	Reduced default mode network functional connectivity in patients with recurrent major depressive disorder. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9078-9083.	7.1	441
76	Integrative analyses of major histocompatibility complex loci in the genome-wide association studies of major depressive disorder. Neuropsychopharmacology, 2019, 44, 1552-1561.	5.4	27
77	Subtypes of treatment-resistant depression determined by a latent class analysis in a Chinese clinical population. Journal of Affective Disorders, 2019, 249, 82-89.	4.1	12
78	The depression GWAS risk allele predicts smaller cerebellar gray matter volume and reduced SIRT1 mRNA expression in Chinese population. Translational Psychiatry, 2019, 9, 333.	4.8	25
79	Prevalence and clinical features of atypical depression among patients with major depressive disorder in China. Journal of Affective Disorders, 2019, 246, 285-289.	4.1	7
80	Complement C7is a novel risk gene for Alzheimer's disease in Han Chinese. National Science Review, 2019, 6, 257-274.	9.5	55
81	The association between somatic symptoms and suicidal ideation in Chinese first-episode major depressive disorder. Journal of Affective Disorders, 2019, 245, 17-21.	4.1	30
82	Introduction. Advances in Experimental Medicine and Biology, 2019, 1180, 1-17.	1.6	3
83	Advance in Diagnosis of Depressive Disorder. Advances in Experimental Medicine and Biology, 2019, 1180, 179-191.	1.6	4
84	Response Inhibition and Emotional Regulation in the Patients with Attention-Deficit/Hyperactivity Disorder and Comorbidity of Disruptive, Impulse-Control, and Conduct Disorders. Psychiatry Investigation, 2019, 16, 872-874.	1.6	4
85	Prevalence, risk factors and clinical characteristics of suicidal ideation in Chinese patients with depression. Journal of Affective Disorders, 2018, 235, 135-141.	4.1	40
86	Assessment and management of bipolar disorder: Principal summary of updated Chinese guidelines. Bipolar Disorders, 2018, 20, 289-292.	1.9	7
87	HTR1A/1B DNA methylation may predict escitalopram treatment response in depressed Chinese Han patients. Journal of Affective Disorders, 2018, 228, 222-228.	4.1	38
88	The Arc Gene Confers Genetic Susceptibility to Alzheimerâ€™s Disease in Han Chinese. Molecular Neurobiology, 2018, 55, 1217-1226.	4.0	30
89	Effects of tumor necrosis factor-Î± polymorphism on the brain structural changes of the patients with major depressive disorder. Translational Psychiatry, 2018, 8, 217.	4.8	25
90	Bloodâ€based dynamic genomic signature for obsessiveâ€“compulsive disorder. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2018, 177, 709-716.	1.7	5

#	Article	IF	Citations
91	Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2473-2484.	2.2	7
92	Somatic symptoms vary in major depressive disorder in China. Comprehensive Psychiatry, 2018, 87, 32-37.	3.1	37
93	The clinical correlates of comorbid anxiety symptoms and syndromal anxiety in patients with major depressive disorder. Psychiatry Research, 2018, 269, 251-257.	3.3	18
94	Association of DNA methylation in BDNF with escitalopram treatment response in depressed Chinese Han patients. European Journal of Clinical Pharmacology, 2018, 74, 1011-1020.	1.9	42
95	Risk Factors for Recent Suicide Attempts in Major Depressive Disorder Patients in China: Results From a National Study. Frontiers in Psychiatry, 2018, 9, 300.	2.6	18
96	Genetic association of the cytochrome c oxidase-related genes with Alzheimerâ€™s disease in Han Chinese. Neuropsychopharmacology, 2018, 43, 2264-2276.	5.4	29
97	Different levels of pro- and anti-inflammatory cytokines in patients with unipolar and bipolar depression. Journal of Affective Disorders, 2018, 237, 65-72.	4.1	47
98	Abnormal white matter integrity in Chinese young adults with first-episode medication-free anxious depression: a possible neurological biomarker of subtype major depressive disorder. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2017-2026.	2.2	13
99	The association of duration and severity of disease with executive function: Differences between drug-naÃ¯ve patients with bipolar and unipolar depression. Journal of Affective Disorders, 2018, 238, 412-417.	4.1	12
100	Analysis of Misdiagnosis of Bipolar Disorder in An Outpatient Setting. Shanghai Archives of Psychiatry, 2018, 30, 93-101.	0.7	33
101	Female-specific effect of the BDNF gene on Alzheimer's disease. Neurobiology of Aging, 2017, 53, 192.e11-192.e19.	3.1	46
102	Increased ratio of high sensitivity C-reactive protein to interleukin-10 as a potential peripheral biomarker of schizophrenia and aggression. International Journal of Psychophysiology, 2017, 114, 9-15.	1.0	24
103	Gender differences in quality of life and functional disability for depression outpatients with or without residual symptoms after acute phase treatment in China. Journal of Affective Disorders, 2017, 219, 141-148.	4.1	13
104	Efficacy and safety of escitalopram in treatment of severe depression in Chinese population. Metabolic Brain Disease, 2017, 32, 891-901.	2.9	14
105	Reduced ENA78 levels as novel biomarker for major depressive disorder and venlafaxine efficiency: Result from a prospective longitudinal study. Psychoneuroendocrinology, 2017, 81, 113-121.	2.7	21
106	Duration of untreated bipolar disorder: a multicenter study. Scientific Reports, 2017, 7, 44811.	3.3	21
107	Identification of plasma biomarkers for distinguishing bipolar depression from major depressive disorder by iTRAQ-coupled LCâ€“MS/MS and bioinformatics analysis. Psychoneuroendocrinology, 2017, 86, 17-24.	2.7	51
108	Common variants at 2q11.2, 8q21.3, and 11q13.2 are associated with major mood disorders. Translational Psychiatry, 2017, 7, 1273.	4.8	9

#	Article	IF	Citations
109	Association analysis between mitogen-activated protein/extracellular signal-regulated kinase (MEK) gene polymorphisms and depressive disorder in the Han Chinese population. Journal of Affective Disorders, 2017, 222, 120-125.	4.1	6
110	Prescribing patterns of psychotropic medications and clinical features in patients with major depressive disorder with and without comorbid dysthymia in China. Asia-Pacific Psychiatry, 2017, 9, e12261.	2.2	1
111	Rare Genetic Variants of the Transthyretin Gene Are Associated with Alzheimerâ€™s Disease in Han Chinese. Molecular Neurobiology, 2017, 54, 5192-5200.	4.0	24
112	Ratio of mBDNF to proBDNF for Differential Diagnosis of Major Depressive Disorder and Bipolar Depression. Molecular Neurobiology, 2017, 54, 5573-5582.	4.0	62
113	Differential gene expression in patients with subsyndromal symptomatic depression and major depressive disorder. PLoS ONE, 2017, 12, e0172692.	2.5	10
114	Fatty acid amide hydrolase inhibitors produce rapid anti-anxiety responses through amygdala long-term depression in male rodents. Journal of Psychiatry and Neuroscience, 2017, 42, 230-241.	2.4	27
115	Complement factor H and susceptibility to major depressive disorder in Han Chinese. British Journal of Psychiatry, 2016, 208, 446-452.	2.8	21
116	Evaluations of treatment efficacy of depression from perspective of both patientsâ€™ symptoms and general sense of mental health and wellbeing: A large scale, multi-centered, longitudinal study in China. Psychiatry Research, 2016, 241, 55-60.	3.3	4
117	Alterations of microRNA-124 expression in peripheral blood mononuclear cells in pre- and post-treatment patients with major depressive disorder. Journal of Psychiatric Research, 2016, 78, 65-71.	3.1	74
118	Identification of SLC25A37 as a major depressive disorder risk gene. Journal of Psychiatric Research, 2016, 83, 168-175.	3.1	24
119	Evaluating the association between the SHANK3 gene and bipolar disorder. Psychiatry Research, 2016, 244, 284-288.	3.3	10
120	Identification of IL6 as a susceptibility gene for major depressive disorder. Scientific Reports, 2016, 6, 31264.	3.3	35
121	Higher Plasma S100B Concentrations in Schizophrenia Patients and Dependently Associated with Inflammatory Markers. Scientific Reports, 2016, 6, 27584.	3.3	32
122	Demographic and clinical differences between early- and late-onset bipolar disorders in a multicenter study in China. Psychiatry Research, 2016, 246, 688-691.	3.3	8
123	Plasma levels of Th17-related cytokines and complement C3 correlated with aggressive behavior in patients with schizophrenia. Psychiatry Research, 2016, 246, 700-706.	3.3	59
124	Validating GWAS-Identified Risk Loci for Alzheimerâ€™s Disease in Han Chinese Populations. Molecular Neurobiology, 2016, 53, 379-390.	4.0	62
125	CFH Variants Affect Structural and Functional Brain Changes and Genetic Risk of Alzheimerâ€™s Disease. Neuropsychopharmacology, 2016, 41, 1034-1045.	5.4	58
126	Neprilysin Confers Genetic Susceptibility to Alzheimerâ€™s Disease in Han Chinese. Molecular Neurobiology, 2016, 53, 4883-4892.	4.0	21

#	Article	IF	Citations
127	PLD3 in Alzheimerâ€™s Disease: a Modest Effect as Revealed by Updated Association and Expression Analyses. Molecular Neurobiology, 2016, 53, 4034-4045.	4.0	30
128	ZNF804A Genetic Variation Confers Risk to Bipolar Disorder. Molecular Neurobiology, 2016, 53, 2936-2943.	4.0	21
129	Important clinical features of atypical antipsychotics in acute bipolar depression that inform routine clinical care: a review of pivotal studies with number needed to treat. Neuroscience Bulletin, 2015, 31, 572-588.	2.9	17
130	Authors' reply. British Journal of Psychiatry, 2015, 206, 79-80.	2.8	0
131	IL-23 and TGF-Î²1 levels as potential predictive biomarkers in treatment of bipolar I disorder with acute manic episode. Journal of Affective Disorders, 2015, 174, 361-366.	4.1	50
132	Atypical features and treatment choices in bipolar disorders: a result of the National Bipolar Mania Pathway Survey in China. Neuroscience Bulletin, 2015, 31, 22-30.	2.9	4
133	Mitochondrial DNA haplogroup B5 confers genetic susceptibility to Alzheimer's disease in Han Chinese. Neurobiology of Aging, 2015, 36, 1604.e7-1604.e16.	3.1	50
134	Down-regulation of PRKCB1 expression in Han Chinese patients with subsyndromal symptomatic depression. Journal of Psychiatric Research, 2015, 69, 1-6.	3.1	6
135	Guidelines concordance of maintenance treatment in euthymic patients with bipolar disorder: Data from the national bipolar mania pathway survey (BIPAS) in mainland China. Journal of Affective Disorders, 2015, 182, 101-105.	4.1	6
136	Dissociated large-scale functional connectivity networks of the precuneus in medication-naÃ¯ve first-episode depression. Psychiatry Research - Neuroimaging, 2015, 232, 250-256.	1.8	65
137	Demographic and clinical differences between early- and late-onset major depressions in thirteen psychiatric institutions in China. Journal of Affective Disorders, 2015, 170, 266-269.	4.1	8
138	Validation of the Chinese Version of the Short TEMPS-A and its application in patients with mood disorders. Journal of Affective Disorders, 2015, 170, 178-184.	4.1	9
139	Surface Vulnerability of Cerebral Cortex to Major Depressive Disorder. PLoS ONE, 2015, 10, e0120704.	2.5	62
140	Risk Factors for Anxiety in Major Depressive Disorder Patients. Clinical Psychopharmacology and Neuroscience, 2015, 13, 263-268.	2.0	24
141	Evaluation of Mood Disorder Questionnaire (MDQ) in Patients with Mood Disorders: A Multicenter Trial across China. PLoS ONE, 2014, 9, e91895.	2.5	14
142	Nerve growth factor variations in patients with mood disorders: no changes in eight weeks of clinical treatment. Neuropsychiatric Disease and Treatment, 2014, 10, 835.	2.2	11
143	Alterations in effective connectivity anchored on the insula in major depressive disorder. European Neuropsychopharmacology, 2014, 24, 1784-1792.	0.7	58
144	Identification of ANKK1 rs1800497 variant in schizophrenia: New data and metaâ€anâ€analysis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 564-571.	1.7	15

#	Article	IF	Citations
145	The efficacy of plasma biomarkers in early diagnosis of Alzheimer's disease. International Journal of Geriatric Psychiatry, 2014, 29, 713-719.	2.7	49
146	Association between brain-derived neurotrophic factor genetic polymorphism Val66Met and susceptibility to bipolar disorder: a meta-analysis. BMC Psychiatry, 2014, 14, 366.	2.6	20
147	Suicide risk in major affective disorder: Results from a national survey in China. Journal of Affective Disorders, 2014, 155, 174-179.	4.1	27
148	Genetic modulation of working memory deficits by ankyrin 3 gene in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 50, 110-115.	4.8	33
149	No association between genetic variants of the LRRK2 gene and schizophrenia in Han Chinese. Neuroscience Letters, 2014, 566, 210-215.	2.1	6
150	Metabolic syndrome in patients taking clozapine: prevalence and influence of catechol-O-methyltransferase genotype. Psychopharmacology, 2014, 231, 2211-2218.	3.1	28
151	A study of N-methyl-D-aspartate receptor gene (GRIN2B) variants as predictors of treatment-resistant major depression. Psychopharmacology, 2014, 231, 685-693.	3.1	65
152	Glutamate receptor 1 phosphorylation at serine 845 contributes to the therapeutic effect of olanzapine on schizophrenia-like cognitive impairments. Schizophrenia Research, 2014, 159, 376-384.	2.0	16
153	Brain-derived neurotrophic factor levels and bipolar disorder in patients in their first depressive episode: 3-year prospective longitudinal study. British Journal of Psychiatry, 2014, 205, 29-35.	2.8	54
154	Altered brain network modules induce helplessness in major depressive disorder. Journal of Affective Disorders, 2014, 168, 21-29.	4.1	57
155	Decreased serum fibroblast growth factor - 2 levels in pre- and post-treatment patients with major depressive disorder. Neuroscience Letters, 2014, 579, 168-172.	2.1	39
156	Influence of BCL2 gene in major depression susceptibility and antidepressant treatment outcome. Journal of Affective Disorders, 2014, 155, 288-294.	4.1	27
157	Elevated serum levels of FGF-2, NGF and IGF-1 in patients with manic episode of bipolar disorder. Psychiatry Research, 2014, 218, 54-60.	3.3	58
158	MiRNA-206 and BDNF genes interacted in bipolar I disorder. Journal of Affective Disorders, 2014, 162, 116-119.	4.1	35
159	Authors' reply. British Journal of Psychiatry, 2014, 205, 410-411.	2.8	1
160	Guidelines Disconcordance in Acute Bipolar Depression: Data from the National Bipolar Mania Pathway Survey (BIPAS) in Mainland China. PLoS ONE, 2014, 9, e96096.	2.5	11
161	Comorbidity of depressive and anxiety disorders: challenges in diagnosis and assessment. Shanghai Archives of Psychiatry, 2014, 26, 227-31.	0.7	53
162	Evaluation of antidepressant polypharmacy and other interventions for treatment-resistant depression. Shanghai Archives of Psychiatry, 2014, 26, 365-7.	0.7	0

#	Article	IF	Citations
163	Neurotrophic Tyrosine Kinase Receptor Type 2 (NTRK2) Gene Associated with Treatment Response to Mood Stabilizers in Patients with Bipolar I Disorder. Journal of Molecular Neuroscience, 2013, 50, 305-310.	2.3	40
164	Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: A report of OPERATION study. Journal of Affective Disorders, 2013, 150, 834-839.	4.1	58
165	The role of BDNF, NTRK2 gene and their interaction in development of treatment-resistant depression: Data from multicenter, prospective, longitudinal clinic practice. Journal of Psychiatric Research, 2013, 47, 8-14.	3.1	56
166	Venlafaxine inhibits the upregulation of plasma tumor necrosis factor-alpha (TNF-Î±) in the Chinese patients with major depressive disorder: A prospective longitudinal study. Psychoneuroendocrinology, 2013, 38, 107-114.	2.7	58
167	Sociodemographic and clinical features of bipolar disorder patients misdiagnosed with major depressive disorder in <scp>C</scp>hina. Bipolar Disorders, 2013, 15, 199-205.	1.9	41
168	Are subsyndromal symptomatic depression and major depressive disorder distinct disorders?. Shanghai Archives of Psychiatry, 2012, 24, 286-7.	0.7	3
169	A Pilot Study of the Efficacy and Safety of Paroxetine Augmented With Risperidone, Valproate, Buspirone, Trazodone, or Thyroid Hormone in Adult Chinese Patients With Treatment-Resistant Major Depression. Journal of Clinical Psychopharmacology, 2011, 31, 638-642.	1.4	47
170	Comparisons of the Efficacy and Tolerability of Extended-Release Venlafaxine, Mirtazapine, and Paroxetine in Treatment-Resistant Depression. Journal of Clinical Psychopharmacology, 2010, 30, 357-364.	1.4	48
171	Biochemical and Endocrine Parameters for the Discrimination and Calibration of Bipolar Disorder or Major Depressive Disorder. Frontiers in Psychiatry, 0, 13, .	2.6	3